- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05264662
Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women
March 2, 2022 updated by: Shabir Madhi
Pertussis (also known as whooping cough) is a highly contagious, vaccine-preventable respiratory tract disease, caused by the bacteria Bordetella pertussis.
It can affect people of all ages, however young unimmunised or partially immunised infants are the most vulnerable group with the highest rates of complications and death.
Recent surveillance data and an increase in the number of pertussis outbreaks being reported nationally, indicate an increase in the incidence of pertussis disease in South Africa.To date there is no data on the effect of vaccinating HIV-infected pregnant women with pertussis-containing vaccines, although there is no reason to think that vaccinating these women would be harmful for them or their foetus.
The knowledge gaps on the immunogenicity, safety and VE of pertussis vaccination of HIV-infected pregnant women should be addressed.
Adacel which is a registered and licensed vaccine manufactured by Sanofi Pasteur, will be tested in this study.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
225
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marta Nunes, PhD
- Phone Number: +27119834283
- Email: marta.nunes@wits-vida.org
Study Locations
-
-
GP
-
Johannesburg, GP, South Africa, 2192
- Chris Hani Baragwanath Academic hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 39 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Pregnant women age ≥18 years to <39 years (vaccinated group only).
- Gestational age 20-36 weeks documented by the approximate date of the last menstrual period and corroborated by physical or sonargraphic exam (vaccinated group only).
- Documented to be HIV-infected or HIV-uninfected.
- Good general maternal health.
- Able to understand and comply with planned study procedures.
- Able and willing to provide written informed consent for themselves and infant
Exclusion Criteria:
- Receipt of any live licensed vaccine ≤14 days prior to study initiation.
- Any significant (in the opinion of the site investigator) acute illness.
- Use of anti-cancer systemic chemotherapy or radiation therapy ≤48 weeks of study enrolment or has immunosuppression as a result of an underlying illness or treatment.
- Long term use of glucocorticoids, including oral or parenteral prednisone ≥20 mg/day or equivalent for more than 2 consecutive weeks (or 2 weeks total) ≤12 weeks of study entry, or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) ≤12 weeks before study entry (nasal and topical steroids are allowed).
- Receipt of corticosteroids for preterm labour ≤14 days before study entry.
- Receipt of immunoglobulin or other blood products (with exception of Rho D immune globulin) ≤12 weeks prior to enrolment in this study or is scheduled to receive immunoglobulin or other blood products (with the exception of Rho D immune globulin) during pregnancy or for the first 24 weeks after delivery.
- Receipt of IL2, IFN, GMCSF or other immune mediators ≤12 weeks before enrolment.
- Uncontrolled major psychiatric disorder.
- History of a severe adverse reaction to previous vaccines (vaccinated group only).
- Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
- Pregnancy complications (in the current pregnancy) such as pre-term labour, hypertension (BP >140/90 in the presence of proteinuria or BP >150/100, with or without proteinuria or currently on antihypertensive medication) and pre-eclampsia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Open label Adacel
Tdap (Adacel) ADACEL (0,5 ml) should be administered as an injection by the intramuscular route. Re-dosing with ADACEL can be used to boost immunity to diphtheria, tetanus and pertussis at 5- to 10-year intervals. ADACEL may be administered to pregnant women during the second and third trimester to provide passive protection to infants against pertussis. |
Administer Adacel to hiv infected and hiv uninfected pregnant mothers
|
No Intervention: control
Infants born to unvaccinated mothers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of antibodies in pregnant women 1 month after vaccination with Tdap.
Time Frame: 24 months
|
To measure antibody responses to all Tdap-IPV antigens (diphtheria, tetanus, PT, FHA, PRN, FIM and polioviruses 1, 2 and 3) in HIV-infected compared with HIV-uninfected pregnant women before and one month after Adacel vaccination.
|
24 months
|
Concentration of antibodies to all Tdap-IPV and Hexavalent antigens in infants.
Time Frame: 24 months
|
To measure antibody responses to all Tdap-IPV and Hexavalent antigens (diphtheria, tetanus, PT, FHA, PRN, FIM, Haemophilus influenzae type-b polyribosyl ribitol phosphate [PRP], polioviruses 1, 2 and 3, and hepatitis B) testing in infants born to mothers who received Adacel during pregnancy and those born to mothers not vaccinated, stratified by maternal HIV status.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transplacental antibody transfer.
Time Frame: 24 months
|
To compare the transplacental antibody transfer ratio of all Tdap-IPV antigens to newborns from HIV-infected mothers and those born to HIV-uninfected mothers vaccinated with Adacel during pregnancy.
|
24 months
|
Vaccination safety
Time Frame: 24 months
|
Number of HIV-infected and HIV-uninfected pregnant women with treatment-related adverse events.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2022
Primary Completion (Anticipated)
May 1, 2025
Study Completion (Anticipated)
June 1, 2025
Study Registration Dates
First Submitted
January 24, 2022
First Submitted That Met QC Criteria
March 2, 2022
First Posted (Actual)
March 3, 2022
Study Record Updates
Last Update Posted (Actual)
March 3, 2022
Last Update Submitted That Met QC Criteria
March 2, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Maternal Pertussis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on dTap Vaccine
-
Children's National Research InstitutePfizerCompletedImmunization | Hepatitis B Vaccine | Poliovirus Vaccine, Inactivated | DTaP Vaccine | MMR Vaccine | HIB-vaccine | Chickenpox Vaccine | Pneumococcal Polysaccharide Vaccine
-
Stanford UniversityActive, not recruitingVaccine Hesitancy | Vaccine Refusal | Vaccine KnowledgeKenya
-
Children's Mercy Hospital Kansas CityCompletedVaccine Hesitancy | Vaccine RefusalUnited States
-
University of OttawaNot yet recruitingPneumococcal Vaccine Uptake | Vaccination Willingness | Pneumococcal Vaccine Knowledge | Pneumococcal Vaccine AttitudeCanada
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
University of PittsburghMerck Sharp & Dohme LLCCompletedQuadrivalent HPV Vaccine | Human Papillomavirus VaccineUnited States
-
PT Bio FarmaCenter for Child Health Universitas Gadjah Mada (CCH-PRO UGM; Cipto Mangunkusumo... and other collaboratorsRecruitingVaccine Adverse Reaction | Vaccine ReactionIndonesia
-
East Carolina UniversityRecruitingVaccine Hesitancy | Structural Barriers | Vaccine TrustUnited States
-
Centre National de la Recherche Scientifique, FranceUniversité Paris-Dauphine; Fondation La main à la pâte; Direction de l Évaluation...CompletedHealth Knowledge, Attitudes, Practice | Vaccine Hesitancy | Vaccine RefusalFrance
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); University of Minnesota; Kaiser PermanenteCompletedHPV Vaccine | Provider Communication Practices | Vaccine Recommendation PracticesUnited States
Clinical Trials on Adacel (Tdap)
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
Scott HalperinSanofi Pasteur, a Sanofi Company; IWK Health CentreCompleted
-
Emory UniversityUniversidad del Valle, GuatemalaCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaCanada
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaUnited States, Canada
-
Mahidol UniversityCompleted
-
Mahidol UniversityCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaJapan
-
Hospital Universitario Dr. Jose E. GonzalezCompleted